Market revenue in 2023 | USD 282.5 million |
Market revenue in 2030 | USD 710.8 million |
Growth rate | 14.1% (CAGR from 2023 to 2030) |
Largest segment | Neurostimulation and neuromodulation devices |
Fastest growing segment | Biomaterials |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Biomaterials, Neurostimulation and Neuromodulation Devices |
Key market players worldwide | Axogen Inc, Stryker Corp, St. Jude Medical, Baxter International Inc, Boston Scientific Corp, Integra Lifesciences Holdings Corp, Medtronic PLC, Polyganics, LivaNova PLC |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to nerve repair and regeneration market will help companies and investors design strategic landscapes.
Neurostimulation and neuromodulation devices was the largest segment with a revenue share of 67.12% in 2023. Horizon Databook has segmented the Japan nerve repair and regeneration market based on biomaterials, neurostimulation and neuromodulation devices covering the revenue growth of each sub-segment from 2018 to 2030.
The nerve repair and regeneration market is growing at a rapid rate in Japan. This can be attributed to technological advancements and rising government initiatives to reduce the risk of neurological diseases. Increase in investments in pharmaceutical companies is anticipated to boost the market growth.
In June 2019, Mesoblast Limited announced that it has expanded its collaboration with JCR Pharmaceuticals Co. Ltd. in Japan to include the use of Mesenchymal Stem Cells (MSCs) in the treatment of newborns with neonatal hypoxic ischemic encephalopathy, a condition in which the brain lacks sufficient blood supply and oxygen (HIE).
In Japan, JCR is launching TEMCELL4 HS Inj., an allogeneic MSC product, for the treatment of steroid-refractory acute graft versus host disease (aGVHD) in children and adults. Mesoblast will receive royalties on all TEMCELL product sales for all licensed indications under the terms of the agreement.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan nerve repair and regeneration market , including forecasts for subscribers. This country databook contains high-level insights into Japan nerve repair and regeneration market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account